RegenerativeMedicine.net

Study Shows Strong Long-Term Survival Rates for Patients with GIST

Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines.

Nine years ago, SWOG researchers based at Oregon Health & Science University (OHSU) confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed as Gleevec. SWOG researchers are back with long-term findings from that study, which estimate that nearly one in four patients treated with Gleevec will survive 10 years.

"This is a really exciting finding," said Dr. Michael Heinrich, a SWOG investigator and a professor of medicine and cell and developmental biology at OHSU. "Until Gleevec arrived on the scene 15 years ago, patients with advanced GISTs faced a life expectancy of 18 months. Now we've learned that some might live a decade or longer. And we've come to understand which class of patients benefits the most from Gleevec."

In new study researchers from SWOG, the international cancer research community supported by the National Cancer Institute, report a follow-up of patients originally enrolled in S0033, a SWOG-led trial supported by other groups in the NCI's National Clinical Trials Network (NCTN). This was a Phase III study that began in 2000. Initial results published in 2008 confirmed Gleevec as an effective treatment for advanced GIST patients, and recommended that therapy start with a 400 mg daily dose. The SWOG team decided to collect post-study data on S0033 patients, and from 2011 to 2015 gathered information. As part of their research, the team used next-generation DNA sequencing on some tumor tissue samples taken for S0033, which had been deposited in a biospecimen bank. The team reanalyzed tissue from 20 patients originally classified as having a wild-type tumor - one without any mutations of KIT, a gene implicated in 85 to 88 percent of all GISTs.

Analysis showed that of the 695 eligible patients originally enrolled in S0033, 189 survived eight years or longer, with a 10-year estimate of overall survival of 23 percent, or nearly one in four patients. DNA sequencing also showed that survival rates were significantly higher for patients with a KIT exon-11 mutant GIST, when compared with patients whose tumor had a KIT exon-9 mutation or with no KIT mutations or mutations in the platelet-derived growth factor receptor gene, or PDGFRA.

"Our findings show two things," Heinrich said. "One is that Gleevec has revolutionized treatment for patients with advanced GISTs. Our findings also highlight the importance of banked biospecimens to drive new scientific findings, and how tumor mutation testing can optimize treatment for cancer patients."

GISTs are different from more common types of gastrointestinal tumors because of the type of tissue in which they start. GISTs belong to a group of cancers called soft-tissue sarcomas. Soft-tissue sarcomas develop in the tissues that support and connect the body, including muscles, nerves, tendons, and joints. GIST is a rare cancer, with about 6,000 new cases diagnosed in the United States each year.

Researchers at OHSU have pioneered the treatment of GISTs. Dr. Brian Druker, director of the OHSU Knight Cancer Institute, conducted the most influential work in the development of Gleevec, and OHSU researchers have been part of major discoveries in the use of the drug to treat GISTs, as well as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

Illustration: Histopathologic image of gastrointestinal stromal tumor of the stomach. Hematoxylin-eosin stain.

Read more...

SWOG News Release (02/20/17)

Science Daily (02/20/17)

Abstract (JAMA Oncology; 2017.)

Tuesday - February 20, 2018

U.S. News
Dealing with Diastasis Recti Study Suggests Way to Attack Deadly, Untreatable Nerve Tumors Clock Protein Controls Daily Cycle of Gene Expression by Regulating Chromosome LoopsWorld News
I came here to work buy herbal viagra nz The IMF hashalved its growth forecast for Russia in 2015 to 0.5 percent,while the World Bank estimates an expansion of only 0.3 percent. Insert your card uses of prozac "It was definitely memorable," Diskerud said of his goal in the 1-1 draw against Ecuador on Friday, his fourth in 22 international appearances I'd like to send this to promethazine vc 6.25-5mg/5ml syrup We don’t lose employees because they don’t want to work there.” Regenerative Medicine Journal
Rev-erbα dynamically modulates chromatin looping to control circadian gene transcription A vitamin B12 conjugate of Exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents Daple coordinates organ-wide and cell-intrinsic polarity to pattern inner-ear hair bundlesPoint Of View
How much does the job pay? vivien plus en couple In the Tulsa suburb of Sand Springs, one person was killed in a trailer park when a tornado ripped through the area I support Manchester United ibuprofen dosage chart adults uk The actress who passed away at age 89 also left money to two of her employees and $250,000 to each of her grandsons About a year promethazine dm syrup buy Hill scored 69 on one intelligence test and in the 70s on other examinations, according to court records.